Track record · closed signal

Merck & Co. Inc. (MRK) — closed signal from April 15, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on July 14, 2026 — +2.3% at the close.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted

$114.35 – $118.29Entry zone — fair-value band

$118.12Published — price the day we called it

$126.66Target — the price the thesis aimed for

$130.29Peak — highest point inside the window, not a realized return

$120.78Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 72 days.

At window close

+2.3%

realized, from the publication price to the last close inside the window

Peak gain

+10.3%

peak, from the publication price — not a realized return

S&P 500, same window

+7.7%

SPY over the identical days, dividend-adjusted

Window close

$120.78

last close inside the window, ended July 14, 2026

Peak price

$130.29

peak on June 30, 2026 — not a realized return

Days to target

The thesis — published April 15, 2026

Predicted growth

+8%

over the measurement window

Target price

$126.66

the price the thesis aimed for

Entry zone

$114.35 – $118.29

the fair-value band we waited for

Price at publication

$118.12

published April 15, 2026

Confidence

70%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Merck looks like a safer healthcare pick for the next few months. A regulatory priority review for a partnered lung cancer drug is a real news event that can lift sentiment. Shares are trading near a lower price area rather than high levels, and earnings are steady rather than fast-growing. It could benefit if investors shift toward more stable names.

Primary drivers

Regulatory priority review provides a clear drug-related news event
Steady earnings make the company more resilient in downturns
Stock trading near a lower price area offers a cleaner entry
Healthcare status helps if investors favor stable sectors

How it played out

MRK: target reached in 72 days

Lyra published MRK at $118.12 with expected growth of 8%. The thesis pointed to a regulatory priority review for a partnered lung cancer drug, steady earnings, a lower price area and the defensive appeal of healthcare if investors favored stable sectors.

The shares reached the $126.66 target in 72 days. They peaked at $130.29 on June 30, a gain of 10.3%. By the end of the window, the price had fallen to $120.78 but remained above the publication price. The thesis played out within the measured period.

What happened during the window

On April 30, Merck reported first-quarter sales of $16.3 billion, up 5%. On May 5, the company completed its acquisition of Terns Pharmaceuticals.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals